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Bacillus thuringiensis crystal Protein Cry5B 
Paraprobiotic 
Inactivated bacterium with cytosolic crystal 
(IBaCC) 
Sheep 
A B S T R A C T   
Haemonchus contortus is a critical parasite of goats and sheep. Infection by this blood-feeding gastrointestinal 
nematode (GIN) parasite has significant health consequences, especially in lambs and kids. The parasite has 
developed resistance to virtually all known classes of small molecule anthelmintics used to treat it, giving rise in 
some areas to multidrug resistant parasites that are very difficult to control. Thus, new anthelmintics are urgently 
needed. Bacillus thuringiensis (Bt) crystal protein 5B (Cry5B), a naturally occurring protein made by a bacterium 
widely and safely used around the world as a bioinsecticide, represents a new non-small molecule modality for 
treating GINs. Cry5B has demonstrated anthelmintic activities against parasites of monogastric animals, 
including some related to those that infect humans, but has not yet been studied in a ruminant. Here we show 
that H. contortus adults are susceptible to Cry5B protein in vitro. Cry5B produced in its natural form as a spore- 
crystal lysate against H. contortus infections in goats had no significant efficacy. However, a new Active Phar-
maceutical Ingredient (API) paraprobiotic form of Cry5B called IBaCC (Inactivated Bacterium with Cytosolic 
Crystals), in which Cry5B crystals are encapsulated in dead Bt cell wall ghosts, showed excellent efficacy in vitro 
against larval stages of H. contortus and relative protein stability in bovine rumen fluid. When given to sheep 
experimentally infected with H. contortus as three 60 mg/kg doses, Cry5B IBaCC resulted in significant reductions 
in fecal egg counts (90%) and parasite burdens (72%), with a very high impact on female parasites (96% 
reduction). These data indicate that Cry5B IBaCC is a potent new treatment tool for small ruminants in the battle 
against H. contortus.   
1. Introduction 
There are many species of gastrointestinal nematodes (GINs) that 
parasitize small ruminants, such as sheep and goats. The main GIN group 
of concern for producers and veterinarians is the trichostrongyles, 
common nematode parasites that cause major production loss and 
disease. They possess a direct life cycle, where the adults in the host 
produce eggs that are shed in the feces. The eggs develop to third stage 
larvae, or L3, in the feces and then circulate into the ambient environ-
ment. The infective L3 stage (L3i) is ingested by the host and develops 
into an egg-laying adult in the gastrointestinal tract of the animal (Scott 
and Sutherland, 2009). One species stands out as particularly 
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pathogenic due to the fact it feeds on blood. This parasite, Haemonchus 
contortus, is an abomasal species that can cause severe anemia, hypo-
proteinemia, weight loss, lethargy, rough hair coats, poor wool/milk/-
meat production, and death in heavily infected individuals (Zajac, 2006; 
Gilleard, 2013). Lambs and kids are at the greatest risk of developing 
disease due to their immature immune response and high rate of 
infection from environmental contamination due to peri-parturient egg 
production by infected ewes and does (Getachew et al., 2007). 
Until recently, this parasite was controlled almost exclusively with 
anthelmintics. Unfortunately, the wide and frequent use of these drugs 
has created selection pressure that favors individual worms resistant to 
these anthelmintics (Kaplan, 2004a). The offspring of the adult parasites 
that survive treatment make up greater and greater portions of the worm 
population as more treatments are administered, leading to a resistant 
population and treatment failures (Jackson and Coop, 2000). Resistance 
in small ruminant GINs has been reported to all widely available an-
thelmintics, including multidrug resistance (Kaplan, 2004b; Wol-
stenholme et al., 2004; Howell et al., 2008; Kaplan and Vidyashankar, 
2012). For each major class of anthelmintic, resistance was reported 
within a decade of the drug becoming commercially available (Kaplan, 
2004b); very recently resistance was seen within a few short years of 
introduction of monepantel, which belongs to one of the newest classes 
of anthelmintics for H. contortus control (Mederos et al., 2014; Van den 
Brom et al., 2015). Thus, anthelmintics involving new mechanisms of 
action are needed. 
We have shown that the nematode-intoxicating crystal (Cry) protein 
Cry5B made by the soil bacterium Bacillus thuringiensis (Bt) has broad in 
vivo anthelmintic properties against GINs in monogastric animals (mice, 
hamsters, dogs, and pigs (Cappello et al., 2006; Hu et al., 2010a; Urban 
et al., 2013; Hu et al., 2018b)). Furthermore, Bt Cry proteins related to 
Cry5B are used safely, globally, and extensively as the number one 
biological insecticide agent in the world, encompassing ~75% of the 
bioinsecticide market and expressed in nearly 100 million hectares of 
transgenic crops (Karthickumar and Balasubramanian, 2017; Xiao and 
Wu, 2019). The main insecticidal components of Bt are three-domain 
Cry proteins, named aptly for their propensity to form large crystals 
(Schnepf et al., 1998; de Maagd et al., 2001). Three-domain Cry proteins 
are pore-forming proteins that specifically bind to and disrupt the 
integrity of the invertebrate gut (Griffitts and Aroian, 2005). There are a 
few reports of using Bt against H. contortus, for example, in vitro studies 
using a Bt strain expressing Cry5B and a larvicidal study using Cry11Aa 
(Kotze et al., 2005; de Lara et al., 2016); however, in all cases there were 
caveats (e.g., the strain was not deconvolved to show specific Cry ac-
tivity or the doses used were very high). 
Here, for the first time, we test the efficacy of Cry5B specifically 
against H. contortus. Cry5B was tested in vitro in a larval development 
assay and then against adult parasites from an H. contortus strain resis-
tant to three classes of anthelmintics (triple anthelmintic resistant). 
Following these in vitro studies, recombinant Cry5B spore-crystal lysates 
were tested against experimental H. contortus infections in goats. Based 
on the results of these studies, a new Active Pharmaceutical Ingredient 
containing Cry5B called Inactivated Bacterium with Cytosolic Crystal 
(IBaCC, a paraprobiotic) was developed and used to treat sheep exper-
imentally infected with H. contortus. Here, we present the results of these 
studies, showing that Cry5B has excellent potential to positively impact 
sheep health and productivity by targeting H. contortus infections and 
reproduction. 
2. Materials and methods 
2.1. Animal approvals 
All protocols in the study were approved by the Virginia Tech 
Institutional Biosafety Committee (IBC, Protocol #17–006) and the 
Institutional Animal Care and Use Committee (IACUC, Protocol 
#18–135, #18–141) and USDA Beltsville IACUC #12–025 and IBC 
#271. 
2.2. H. contortus in vitro assays 
Parasite eggs were isolated from infected sheep stool as described 
(Mes et al., 2007). Egg-to-larval assays (larval development assays) were 
carried out as described as for C. elegans and cyathostome eggs (Hu et al., 
2010b, 2018a). Briefly, parasite eggs were placed in S Medium in a 
96-well format supplemented with Escherichia coliOP50 and incubated 
at 25 ◦C for seven days. The total number that developed to the L3i stage 
were counted. Feces from sheep experimentally mono-infected with 
H. contortus were shipped overnight from Virginia Tech to the Aroian 
Lab for these studies. Cry5B IBaCC was prepared as described (Li et al., 
2020). 
Adult H. contortus (Isolate Hc/2004A originally provided by Dr. Ray 
Kaplan under an MTA between the University of Georgia and USDA/ 
ARS) was isolated from French Alpine goats. This strain is resistant to 3 
major classes of anthelmintics 1) benzimidazole (fenbendazole, alben-
dazole, others), 2) imidazothiazole/tetrahydropyrimidine (levamisole, 
morantel, others) and 3) avermectin (ivermectin, doramectin, others), 
and slightly resistant to moxidectin. Three goats each at approximately 
three months of age were orally inoculated with a single dose of 5000 
H. contortus L3i and maintained for an additional 50 days (primary 
infection). At 50 days post inoculation (dpi), the goats were euthanized 
and adult worms were screened from the abomasal contents then pan-
ned using a glass bowl and fine forceps to remove the worms. Tubes 
containing about 20–30 adult worms were placed in 50 ml of RPMI-1640 
media with antibiotics after washing by sedimentation at least 10 times 
in sterile media and shipped overnight to the Aroian laboratory. In vitro 
assays were carried out as described for hookworms using the same 
medium, same temperature, and same CO2 concentration with the 
addition of 25 mM HEPES pH 7.2 (Cappello et al., 2006; Hu et al., 2012, 
2013a) in a 24-well plate with volume of 500 μL, four adult H. contortus 
per well, and two wells per dose. Cry5B was purified from spore crystal 
lysates as described (Griffitts et al., 2001). Adult parasites were scored 
once per day as live/dead as described (dead = no motility even after 
repeated touching); (Hu et al., 2013a; Urban et al., 2013). 
2.3. In vivo goat study 
Male Sire (Boer) x Dam (Kiko x Savanna x Boer) goats 19–28 weeks of 
age were purchased locally before relocating to a pasture at the Belts-
ville Agricultural Research Center in early spring; the pasture had been 
free of livestock for the previous three years. Goats on pasture were 
supplemented ad libitum with orchard grass hay. The goats had been 
treated with moxidectin by the producer 26 days before shipment and 
received a CDT vaccine at 26 and 5 days prior to arrival in Beltsville. 
Initial egg counts from feces were evaluated as described (Gasbarre 
et al., 2015). Upon arrival in Beltsville, the goats showed strongyle eggs 
at <50 eggs per gram of feces or epg in 7 of 24 goats (the remainder had 
no strongyle eggs), Moniezia proglottids in 7 of 24, Strongyloides eggs in 
10 of 24 goats, Trichuris eggs in 1 of 24 goats and coccidia oocysts in all 
samples. The average initial body weight was 27.3 kg (22–34 kg range). 
All goats were given a subcutaneous injection of 200 mg of ceftiofur 
hydrochloride upon arrival in Beltsville. 
Haemonchus contortus L3i were obtained from sheep infected at 
Virginia Tech (see below for details) and sent overnight as a suspension 
to Beltsville. The goats were each subsequently given an oral inoculation 
of 5000 H. contortus L3i per animal two weeks after arrival and place-
ment on pasture. Weights and fecal samples were collected after three 
weeks to evaluate the acquisition of parasite infection and changes in 
weight. The average weight at that time was 26.8 kg (19–33 kg range) 
with an average strongyle epg of 5843 (8–21,249 range). Full fecal egg 
counts of all relevant time points are given in Fig. S1. Two weeks later, 
goats were relocated to an open-aired concrete-surfaced enclosure and 
randomly assigned to three groups of eight designated as 1) untreated, 
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2) Cry5B-SCL-treated twice (40 mg/kg body weight once per day one 
day apart) and 3) moxidectin-treated (single dose 0.2 mg/kg body 
weight), with groups 2 and 3 inoculated by oral gavage. Cry5B SCL was 
prepared as described (Marroquin et al., 2000; Hu et al., 2010a). The 
goats were fed orchard grass hay ad libitum and a supplement of pelleted 
grain concentrate while on the enclosure. 
For oral dosing, animals were manually restrained, and the anthel-
mintic suspensions were given with a 50 ml syringe and ball-tipped 
inoculating needle. Animals were observed daily for any adverse re-
actions; none were seen throughout the course of the study. The nec-
ropsy of the goats was conducted over three days between eight and 10 
days after moxidectin treatment and after the initial treatment with a 
two-dose regimen of Cry5B-SCL based on the logistics of availability of 
facilities and personnel. After euthanasia, the contents of the abomasum 
and small intestine, a rectal fecal sample, and tissue from the large in-
testine were collected. Fecal egg counts (Gasbarre et al., 2015) were 
determined from feces taken from the rectum at necropsy. The 
abomasum and small intestine contents were evaluated for parasite 
burden using a modified agar gel method originally used to detect 
luminal parasites of swine (Slotved et al., 1996; Urban et al., 2013). Very 
few parasites were found in the contents from the small intestine. Ali-
quots of samples of abomasum contents collected from the gel after a 3-h 
incubation in normal saline at 37C were examined for worms using a 
dissecting microscope and gridded Petri dish. All worms present from 
the abomasum contents were identified as adult H. contortus based on 
morphologic characteristics. 
2.4. In vitro rumen fluid stability study 
Cry5B crystals were isolated from Cry5B IBaCC (Li et al., 2020) and 
incubated in duplicate in cow rumen fluid for 12, 24, or 48 h as 
described (Goeser, 2008; Goeser et al., 2009; Goeser and Combs, 2009). 
Incubations were carried out courtesy of Zinpro Corporation. To deter-
mine any percent degradation of Cry5B, the amount of full length Cry5B 
was quantitated by SDS PAGE relative to BSA standards and compared to 
the total amount used in the in vitro assay. 
2.5. In vivo sheep study 
Dorset, Suffolk, and Dorset/Suffolk cross lambs aged 7–8 months 
were used for this study. The six female and six castrated male lambs had 
been previously pastured but were maintained in housing for the 
duration of the study to prevent additional natural H. contortus exposure. 
All animals were orally administered albendazole (7.5 mg/kg), iver-
mectin (0.2 mg/kg), and levamisole (8.0 mg/kg) sequentially to remove 
existing strongylid infection. Sheep were orally inoculated with 10,000 
H. contortus L3i six weeks prior to beginning IBaCC treatment. The 
H. contortus L3i used for infection were obtained from feces of a sheep 
with a monoinfection of H. contortus. Fecal samples were collected once 
weekly to determine fecal egg counts (FEC) for each animal. To deter-
mine FEC, fecal samples were collected rectally from the sheep and 
analyzed using the Mini-FLOTAC® test (University of Naples Federico II, 
Naples, Italy) with a detection limit of 5 eggs per gram of feces (EPG). 
The day before treatment began, sheep were weighed to determine 
the treatment dose required for each animal and divided into experi-
mental groups balanced for mean FEC with an equal number of males 
and females in each group. Mean FEC was determined using the previous 
three weeks FEC data for each sheep. Each animal in the treatment group 
received a suspension of 60 mg/kg of Cry5B IBaCC in water, adminis-
tered orally by syringe. Animals in the control group received 200 mL of 
water orally. Treatments were carried out at approximately the same 
time of day on three consecutive days (see Fig. 5A). FEC were deter-
mined daily. Fecal samples on Days 1–3 were collected before treatment 
was given. On Day 8, the sheep were humanely euthanized. A 20% 
aliquot of abomasal contents was collected from each animal. An equal 
volume of 10% formalin was used to fix the worms. One control animal’s 
abomasal contents were unfortunately lost during collection. The 
number of worms in the entire 20% aliquot of abomasal contents from 
each animal was counted using a dissecting microscope and gridded 
Petri dish. All worms present were identified as adult Haemonchus con-
tortus based on morphologic characteristics. 
2.6. Statistics 
All graphs and analyses were generated using GraphPad Prism v. 8. 
The comparisons between multiple groups in the goat study were carried 
out using one-tailed Dunnett’s multiple comparison test, comparing to 
control. The comparison of FEC in the sheep study (Fig. 5B) was carried 
out using two-way analysis of variance (mixed-effects analysis Time x 
Treatment, as there was one data point missing for one sheep). All 
comparisons between two groups were carried out using one-tailed 
Mann-Whitney test with the assumption that treatment would reduce 
the infection, except for starting FEC for the sheep study (two-tailed 
Mann-Whitney to test for equality at the beginning). 
3. Results 
3.1. Cry5B is active against H. contortus adults in vitro 
We first determined if Cry5B on its own was active against 
H. contortus. Adult parasites from a triple anthelmintic-resistant strain of 
H. contortus maintained at the USDA were isolated from French-Alpine 
goats and set up for testing an in vitro dose-response using Cry5B puri-
fied from spore-crystal lysates (SCLs) (Griffitts et al., 2001, 2005; Cap-
pello et al., 2006). We found that purified Cry5B intoxicates triple 
anthelmintic-resistant adult H. contortus (Fig. 1). 
3.2. Cry5B spore crystal lysate was not effective against H. contortus in 
goats 
We next tested whether Cry5B spore crystal lysates could be used 
against an experimental H. contortus infection in goats. SCLs are formed 
when Bt sporulates, producing crystal(s) in the cytosol of the mother 
cell. The cell subsequently lyses and releases the crystal(s) and the spore. 
SCLs are the form of Bt Cry proteins used in topical applications 
worldwide as insecticides (Roh et al., 2007; Koch et al., 2015). Goats 
experimentally infected with H. contortus larvae were treated with either 
nothing (placebo, negative control), Cry5B SCL (40 mg/kg) given twice 
one day apart per os, or a single dose of moxidectin (0.2 mg/kg; positive 
control). Moxidectin treatment resulted in a statistically significant drop 
Fig. 1. Effects of purified Cry5B on H. contortus adults. Triple anthelmintic- 
resistant H. contortus adults were incubated in vitro with varying concentra-
tions of purified Cry5B and scored for live or dead (no movement even after 
touch). Intoxication in this scoring scheme is seen at 100 and 1000 μg/mL. All 
other doses overlapped completely with HEPES control. 
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in parasite burdens and fecal egg counts (FEC), while Cry5B SCL treat-
ment did not, although both parasite burdens and FEC for Cry5B treated 
goats were slightly lower than control (see Fig. 2). 
3.3. The paraprobiotic Cry5B IBaCC is effective against H. contortus 
larvae and crystals are stable in rumen fluid 
We recently developed a new Active Pharmaceutical Ingredient 
(API) containing Cry5B called IBaCC for inactivated bacterium with 
cytosolic crystal (Fig. 3A (Li et al., 2020)). In this form, Cry5B is 
expressed in a sporulation defective Bt strain under control of a 
non-sporulating promoter, giving rise to production of a Cry5B crystal 
inside a vegetative Bt cell. This vegetative Bt is then inactivated (killed) 
with food-grade plant essential oil (monoterpenoid), giving rise to a 
dead bacterial cell wall ghost, harboring within its peptidoglycan shell a 
Cry5B crystal that is fully bioactive. Such a dead probiotic is known as a 
paraprobiotic (Taverniti and Guglielmetti, 2011). An appropriate 
negative control for IBaCC is IBa (inactivated bacterium). IBa is identical 
to IBaCC in all ways except that the plasmid harboring the Cry5B gene 
has no insert (empty vector). The parent Bt strain, plasmid backbone, 
and all processing steps are otherwise identical for IBa and IBaCC. 
Although we were no longer able to access H. contortus adults for 
Cry5B efficacy testing, we were able to obtain fecal samples from 
H. contortus-infected sheep to evaluate larval development in vitro in the 
presence/absence of Cry5B IBaCC. From these fecal samples, we isolated 
parasite eggs and carried out egg to larval development assays in a 96 
well format culture system over the course of 7 days as described (Hu 
et al., 2018a). Three independent experiments were carried out, looking 
to see how many H. contortus eggs developed to the infective L3 stage 
(L3i) in 7 days at 28 ◦C. As shown (Fig. 3B), H. contortus larval devel-
opment is exquisitely sensitive to Cry5B IBaCC, showing near complete 
(98%) inhibition at 56 ng/mL. These results were confirmed with an 
independent batch of IBaCC, showing complete (100%) inhibition of L3i 
development at 37.5 ng/mL (Fig. S2). 
These results demonstrated that IBaCC was potent against 
H. contortus larvae. Since the goat study failed to show an effect of Cry5B 
on H. contortus, we were concerned that Cry5B crystals might not be 
stable during passage through the rumen. To determine if Cry5B from 
IBaCC might be stable in a ruminant, Cry5B crystals isolated from Cry5B 
IBaCC were incubated in cow rumen fluid in vitro for 12, 24, and 48 h. No 
appreciable degradation was seen at 12 and 24 h (Fig. 4). At 48 h, 
approximately 40% of the Cry5B was degraded, indicating that Cry5B 
crystals in IBaCC would be stable up to 24 h in the rumen after ingestion 
and passage to the abomasum. 
3.4. Cry5B IBaCC is effective against H. contortus infestations in sheep 
Based on Cry5B IBaCC efficacy against H. contortus larvae and on 
stability studies with Cry5B IBaCC crystals in rumen fluid, we tested the 
efficacy of Cry5B IBaCC against H. contortus infections in sheep 
(Fig. 5A). Twelve sheep were experimentally inoculated with 
H. contortus L3i. Fecal samples were taken and pre-treatment FEC were 
determined on the day of treatment with IBaCC. Six sheep were given 
Fig. 2. Cry5B SCL treatment of H. contortus infected goats (n = 8 per group). 
(A) Abomasal H. contortus burdens of goats untreated (control), treated with 
Cry5B in SCL, or treated with moxidectin (positive control). Moxidectin treat-
ment resulted in a 62% reduction relative to control. (B) Corresponding fecal 
egg counts. Moxidectin treatment resulted in an 84% reduction relative to 
control. Bar represents the average burden. Numbers shown are P values rela-
tive to control. 
Fig. 3. IBaCC. (A) Photomicrograph of IBaCC showing dead Bt cells and 
encapsulated crystals (dark inclusions). Scale bar is 5 μM. (B) Efficacy of Cry5B 
IBaCC against H. contortus egg-to-larval development showing number of eggs 
that developed to the L3i stage over seven days in various concentrations of 
Cry5B IBaCC (average of three independent experiments). Each concentration 
of IBaCC had a corresponding concentration of IBa (empty vector control 
bacteria containing no Cry5B) normalized for OD600. Error bars here and 
elsewhere represent standard error of the mean. 
Fig. 4. Stability of Cry5B IBaCC crystals in cow rumen fluid. Sodium Dodecyl 
Sulfate–Polyacrylamide Gel Electrophoresis (SDS-PAGE) of Cry5B IBaCC crys-
tals after incubation for indicated number of hours in cow rumen fluid. Arrow 
points to full-length Cry5B protein. Although the input Cry5B was not run on 
the gel, relative to the amount of Cry5B put into the rumen fluid, there is no 
significant degradation of Cry5B at 12 and 24 h (see methods). 
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water (placebo control) and six sheep were given 60 mg/kg Cry5B in 
IBaCC daily for three consecutive days. Fecal egg counts were deter-
mined daily (on days when treatment occurred, fecal samples were 
taken before treatment). The sheep were euthanized seven days after the 
first treatment to determine the worm burden in the abomasum. 
Sharp reductions in FEC were seen within two days after treatment 
that was statistically significant (Fig. 5B). Although starting FEC were 
similar in both control and treated groups, by the end of the study they 
were statistically much lower in the treated group (Fig. 5C). Between 
88% and 96% reductions in FEC were seen relative to untreated controls 
starting three days after the first treatment. 
By the end of the study, parasite burdens in Cry5B IBaCC treated 
sheep were significantly reduced 72% relative to infected but untreated 
control sheep (Fig. 6A). The larger reduction in FEC relative to reduced 
adult worm burden was likely due to a 96% reduction in female worms 
versus a 60% reduction in male worms (both statistically significant; 
Fig. 6B and C). 
4. Discussion 
New therapies against H. contortus in small ruminants are desper-
ately needed due to the highly pathogenic nature of the parasite and its 
propensity for developing anthelmintic drug resistance to small mole-
cules. Here, we have shown in vitro that Cry5B protein intoxicates adult 
H. contortus parasites and is very potent against H. contortus larval 
development (complete inhibition ~50 ng/mL). We have presented data 
showing for the first time that a Bt Cry protein, Cry5B, when produced as 
part of the paraprobiotic IBaCC (crystal encapsulated within the shell of 
an inactivated bacterium), significantly reduced H. contortus infection in 
sheep. Three 60 mg/kg doses of Cry5B in IBaCC cleared >70% of the 
adult parasites and 96% of the female parasites, which led to a com-
parable reduction in parasite FEC. Although three doses were given, 
further testing may show that 1–2 doses can achieve a biologically sig-
nificant effect that reduces infection transmission. Further dosing 
studies to determine the minimal effective dose and development of 
formulations to promote delivery to the abomasum and posterior GI 
tract are warranted. 
Fig. 5. Experimental design and FECs of curative sheep study with IBaCC (n = 6 sheep/group). (A) Experimental design of sheep study. (B) Fecal egg counts (FECs) 
over time (eggs per gram of feces) relative to the day of first treatment for control (water) and treated (IBaCC) groups (six sheep per group). FECs were always 
determined before treatment on any given day. The difference between fecal egg counts between control and treated groups based on two-way analysis of variance (P 
= 0.0009) was significant. (C) Comparison of starting and ending FECs for both groups. 
Fig. 6. H. contortus abomasal parasite burdens in curative sheep study with IBaCC. (A) Total parasite burdens in control vs IBaCC treated sheep. (B) Male parasite 
burdens in control vs IBaCC treated sheep. (C). Female parasite burdens in control vs IBaCC treated sheep. Data from one sheep in the control group was not collected 
(see Materials and Methods). 
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Our data show that Cry5B crystals from IBaCC will survive the rumen 
and that H. contortus adults can ingest Cry5B since they are intoxicated in 
vitro. How Cry5B is ingested by H. contortus in the abomasum is an area 
for investigation but there is precedent for a blood feeder accessing 
Cry5B in vivo with hookworms (Kalkofen, 1970; Cappello et al., 2006; 
Hu et al., 2012, 2013b, 2018a, 2018b; Wu et al., 2015; Li et al., 2020). 
Although Cry5B IBaCC was effective in H. contortus-infected sheep, 
we found that Cry5B delivered as part of Bt spore crystal lysates (SCLs) 
had no significant impact on H. contortus infections in goats. The reasons 
for these disparate results are yet unclear but could include: 1) differ-
ences between goats and sheep; 2) differences in dosing (2 × 40 mg/kg 
versus 3 × 60 mg/kg); and/or 3) differences between spore crystal ly-
sates and IBaCC and the ability of IBaCC and/or Cry5B crystals in IBaCC 
to better survive rumen conditions before entering the abomasum to 
intoxicate H. contortus. 
The mechanism of action of Cry5B has been studied extensively in 
C. elegans and to some extent in hookworms and Ascaris, where the 
mechanism of action was shown to be conserved with C. elegans (Cap-
pello et al., 2006; Hu et al., 2012; Urban et al., 2013). Cry5B, which is a 
three-domain Cry protein, needs to be ingested by the target nematode 
to act, following which it binds to invertebrate-specific glyco-
sphingolipids on nematode intestinal cells and forms pores, resulting in 
intoxication, dysfunction, and death as has been demonstrated in insects 
targeted by three-domain Cry proteins (Griffitts et al., 2001, 2003, 2005; 
Huffman et al., 2004; Griffitts and Aroian, 2005; Barrows et al., 2007; 
Bischof et al., 2008; Kao et al., 2011; Los et al., 2011; Hui et al., 2012). 
The mechanism of action against H. contortus is likely the same and can 
be subjected to more study in the future (e.g., investigation of Cry5B 
binding to H. contortus intestinal glycosphingolipds). 
Other studies have examined the impact of Bt and Cry proteins on 
H. contortus. One group showed that a Cry5B-containing strain of Bt was 
toxic to H. contortus adults and larvae (Kotze et al., 2005). Although this 
study did not confirm that the anthelmintic activity was due to Cry5B 
since other Cry proteins were also produced by this strain, the level of 
toxicity against larvae and adults in vitro was remarkably similar to that 
shown here (Figs. 1 and 3), suggesting that Cry5B was likely the active 
component in those studies. In other studies, either the toxicity seen (e. 
g., against larvae) was 2-3 orders of magnitude less effective than shown 
here, or the doses used were not indicated, or the efficacy could not be 
attributed to Cry protein (e.g., activity was seen against non-feeding egg 
stages or activity seen when soluble fractions were injected by intra-
peritoneal or intramuscular routes) (Lopez-Arellano et al., 2002; Lopez 
et al., 2006; Linares et al., 2008; Vázquez-Pineda et al., 2010; Sinott 
et al., 2012; de Lara et al., 2016; Beena et al., 2019). 
One interesting finding here was the higher sensitivity of female 
versus male H. contortus in vivo. Since Cry proteins need to be ingested to 
intoxicate, this may mean that the females are feeding more than males 
or their feeding behavior is more conducive towards ingesting Cry 
proteins. The significant difference in size between female and male 
worms are consistent with the former. Alternatively, the metabolic re-
quirements of egg-producing females may make them more sensitive to 
intoxication. 
Development of anthelmintic resistance in H. contortus is an impor-
tant consideration. In this regard, Cry5B may have some advantages. 
Forward genetic screens for resistance showed that it is 3X more difficult 
for C. elegans to develop resistance to Cry5B than to benzimidazoles and 
nicotinic acetylcholine receptor (nAChR) agonists (Hu et al., 2010b). 
Furthermore, Cry5B worked synergistically with nAChR agonists and 
showed mutual hyper-susceptibility (e.g., nematodes resistant to nAChR 
agonists are hyper-susceptible to Cry5B) (Hu et al., 2010b, 2018a). To 
our knowledge, no other anthelmintic combinations showed both these 
properties. These data predict that exposure of GI parasites to Cry5B in 
combination with anthelmintics like pyrantel, tribendimidine, and le-
vamisole would limit the induction of resistance (Hu et al., 2010b, 
2018a). Finally, it has been shown that pyramiding (combinations of) 
insecticidal Cry proteins can provide significant protection against the 
development of resistance by insects, even under high selective pressure 
(Roush, 1998; Shelton et al., 2000; Stewart et al., 2001; Cao et al., 2002; 
Tabashnik et al., 2003; Zhao et al., 2003; Bates et al., 2005; Yang et al., 
2011). Thus, Cry5B could eventually be combined with other Cry pro-
teins to impede the development of parasite resistance by GIN parasites 
of livestock and humans. 
Our data indicated that Cry5B IBaCC has significant potential to 
augment current control strategies against H. contortus infections in 
sheep and to overcome parasite resistance to drugs currently used to 
control this important parasite of ruminants. 
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